scholarly journals Preconcentration and Detection of Gefitinib Anti-Cancer Drug Traces from Water and Human Plasma Samples by Means of Magnetic Nanoparticles

Nanomaterials ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 1196 ◽  
Author(s):  
Hadeer Borg ◽  
Dániel Zámbó ◽  
Heba Elmansi ◽  
Heba M. Hashem ◽  
Jenny Jehan Nasr ◽  
...  

Along of widespread application of anti-cancer drug Gefitinib (GEF), it appears in human body fluids as well as clinical wastewater. Consequently, a reliable and easy-to-adapt detection technique is of essential importance to quantify the drug in different media. The extraction and quantitative detection of anti-cancer drug Gefinitib (GEF) is demonstrated based on a straightforward and efficient magnetic nanoparticle-assisted preconcentration route from water and human plasma samples. Iron oxide magnetic nanoparticles (Fe3O4) have been prepared with an average particle size of 15 nm and utilized as extractible adsorbents for the magnetic solid-phase extraction (MSPE) of GEF in aqueous media. The method is based on MSPE and preconcentration of GEF followed by High-Performance Liquid Chromatography-Ultraviolet Detection (HPLC-UV). The yield of GEF extraction under the optimum MSPE conditions were 94% and 87% for water and plasma samples, respectively. The chromatographic separation was carried out isocratically at 25 °C on a Phenomenex C8 reversed phase column (150 mm × 4.6 mm, with 5 µm particle size). The proposed method was linear over concentration ranges of 15.0–300.0 and 80.0–600.0 ng/mL for water and plasma samples with limits of detection of 4.6 and 25.0 ng/mL in a respective order. Relative standard deviations (%RSD) for intra-day and inter-day were 0.75 and 0.94 for water samples and 1.26 and 1.70 for plasma samples, respectively. Using the magnetic nanoparticles (MNPs) as loaded drug-extractors made the detection of the anti-cancer drug environmentally friendly and simple and has great potential to be used for different drug-containing systems.

2014 ◽  
Vol 50 (5) ◽  
pp. 590-592 ◽  
Author(s):  
Abdallah A. Yassin ◽  
Ahmed M. Elwaseef ◽  
Magdy M. Elnashar ◽  
Johannes Oldenburg ◽  
Günter Mayer ◽  
...  

Author(s):  
Brady R Cunningham ◽  
Rebecca M Coleman ◽  
Adam M Schaefer ◽  
Elizabeth I Hamelin ◽  
Rudolph C Johnson

Abstract Florida red tides have become more common and persistent in and around the Gulf of Mexico. When in bloom, red tides can produce brevetoxins in high concentrations, leading to human exposures primarily through contaminated food and ocean spray. The research described here includes adapting and validating a commercial brevetoxin water test kit for human plasma testing. Pooled plasma was fortified with a model brevetoxin, brevetoxin 3, at concentrations from 0.00500 to 3.00 ng/mL to generate calibration curves and quality control samples. The quantitative detection range was determined to be 0.0400–2.00 ng/mL brevetoxin 3 equivalents with inter- and intraday accuracies ranging from 94.0% to 109% and relative standard deviations <20%, which is within the US Food and Drug Administration guidelines for receptor-binding assays. Additionally, cross-reactivity was tested using 4 of the 10 known brevetoxins and 12 paralytic shellfish toxins. The cross-reactivity varied from 0.173% to 144% for the commercially available brevetoxin standards and 0% for the commercially available paralytic shellfish toxin standards. Fifty individual unexposed human plasma samples were measured to determine the limit of detection and endogenous interferences to the test. The validated method was used to test 31 plasma samples collected from humans potentially exposed to brevetoxins, detecting 11 positives. This method has been proven useful to measure human exposure to brevetoxins and can be applied to future exposure events.


Author(s):  
Mehwish Mushtaq ◽  
Yasar Shah ◽  
  Samiullah ◽  
Fazli Nasir ◽  
Haroon Khan ◽  
...  

Abstract In this research work, an isocratic, reversed-phase high-performance liquid chromatography-ultraviolet/visible detector method was developed for analysis of voriconazole standard (stock-solution) and in plasma samples. Optimization and validation of the method was carried out as per international guidelines. The method offered a simple liquid–liquid extraction technique, which exhibited best recovery of voriconazole along with fluconazole, i.e., internal standard. Different experimental conditions were tried and ultimately, the best outcomes were accomplished utilizing C-18 Perkin-Elmer® column with particulars of 150 mm length, 4.6 mm inner diameter and 5 μm particle size, protected by an RP-18 Perkin-Elmer® Pre-column guard cartridge with specifications of 10 μm particle size, 30 mm length and 4.6 mm inner diameter, utilizing mobile-phase of acetonitrile-water (ACN: H2O) in proportion of 60: 40 v/v, having a flow rate of 1.5 mL/min, and wavelength of 254 nm. All the analytes were observed to be separated in ≤7 min. A linear calibration curve was obtained at concentration range of 01–10 μg/mL of voriconazole. The correlation coefficient of voriconazole was observed to be 0.999, and average recovery (in percent) was 97.4%, whereas the relative standard deviation value was ≤2%. The lower limit of detection was 0.01 μg/mL, whereas, lower limit of quantification was 0.03 μg/mL, respectively. This developed method provided outstanding results of all validation parameters, i.e., recovery, accuracy, selectivity, precision and reproducibility. The method proposed for voriconazole analysis was applied effectively for further research investigation of voriconazole in human-plasma samples (to assess the pharmacokinetic parameters), pharmaceutical formulations and pharmacokinetic drug–drug interaction’s.


RSC Advances ◽  
2015 ◽  
Vol 5 (97) ◽  
pp. 79433-79439 ◽  
Author(s):  
Najmeh Delaviz ◽  
Pooria Gill ◽  
Abolghasem Ajami ◽  
Mohsen Aarabi

Described here is a methodology for selectively capturing HCV particles from human plasma samples using aptamer-conjugated magnetic nanoparticles. The aptamers were specifically bound to the E1E2 glycoprotein of HCV viruses.


2021 ◽  
Vol 2 (3) ◽  
pp. 100606
Author(s):  
Giuseppina E. Grieco ◽  
Guido Sebastiani ◽  
Daniela Fignani ◽  
Noemi Brusco ◽  
Laura Nigi ◽  
...  

2006 ◽  
Vol 29 (15) ◽  
pp. 2265-2283 ◽  
Author(s):  
Gorka Iriarte ◽  
Nerea Ferreirós ◽  
Izaskun Ibarrondo ◽  
Rosa Maria Alonso ◽  
Miren Itxaso Maguregi ◽  
...  

2012 ◽  
Vol 11 (7) ◽  
pp. 3774-3781 ◽  
Author(s):  
Gwenael Pottiez ◽  
Jayme Wiederin ◽  
Howard S. Fox ◽  
Pawel Ciborowski

Sign in / Sign up

Export Citation Format

Share Document